NEWS AND INSIGHTS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

05/09/2023

Halozyme to Present at Upcoming Investor Conferences

05/03/2023

Halozyme To Report First Quarter 2023 Financial and Operating Results

04/25/2023

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

03/15/2023

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS

02/21/2023

Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results

02/07/2023

Halozyme Appoints Barbara Duncan to its Board of Directors

02/06/2023

HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024

01/11/2023

Halozyme Provides 2023 Financial Guidance and Outlook

01/10/2023

Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference

01/03/2023
View All Press Releases
All 3
All 3 /Company Updates 1 /Executive Insights 1 /Values Series 1

Insights Value Series: Introduction

April 5, 2022/by ehennes

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

August 9, 2021/by David Anderson

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

January 28, 2021/by David Anderson

Press Releases

  • 05/21/21

    Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

  • 05/10/21

    Halozyme Reports First Quarter 2021 Results

  • 04/29/21

    Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

  • 04/20/21

    Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

  • 02/24/21

    Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

  • 02/10/21

    Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

  • 01/15/21

    Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

  • 01/11/21

    Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

  • 01/04/21

    Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

Insights

Insights Value Series: Introduction

/in /by

We want to provide some insight into our company’s values in an ongoing series on Halozyme’s Insights webpage. This series is an opportunity…

Read more

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

/in /by

Thank you to our patients, partners and shareholders for your continued support as we’ve learned to navigate through these unprecedented times…

Read more

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

/in /by

When it comes to implementing strong pharmacovigilance practices at your company, there are a variety of components and capabilities…

Read more

Copyright© 2015-2023. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.